Inventiva's Phase 2 Results Boost Hope for MASH Treatment

TipRanksNov 15 16:57 ET

Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their...

BenzingaNov 15 16:01 ET

UBS Initiates Inventiva(IVA.US) With Hold Rating, Announces Target Price $3

Moomoo NewsNov 12 05:37 ET · Ratings

Cautious Optimism for Inventiva's Lanifibranor Amidst Execution Challenges and Dilution Risks

TipRanksNov 12 05:05 ET

Inventiva Initiated With a Neutral at UBS

TipRanksNov 12 05:00 ET · Ratings

Inventiva's Strategic Moves at Upcoming General Meeting

TipRanksNov 4 08:57 ET